BR112017025995A2 - inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal - Google Patents

inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal

Info

Publication number
BR112017025995A2
BR112017025995A2 BR112017025995-8A BR112017025995A BR112017025995A2 BR 112017025995 A2 BR112017025995 A2 BR 112017025995A2 BR 112017025995 A BR112017025995 A BR 112017025995A BR 112017025995 A2 BR112017025995 A2 BR 112017025995A2
Authority
BR
Brazil
Prior art keywords
intestinal disorder
diagnosis
igfbp3
inhibitor
prevention
Prior art date
Application number
BR112017025995-8A
Other languages
English (en)
Inventor
D'addio Francesca
Fiorina Paolo
Original Assignee
Ospedale San Raffaele S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale San Raffaele S.R.L. filed Critical Ospedale San Raffaele S.R.L.
Publication of BR112017025995A2 publication Critical patent/BR112017025995A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Abstract

a presente invenção se refere a um inibidor de igfbp3 e usos dele para o tratamento e/ou prevenção de uma doença intestinal, em particular, de enteropatia diabética ou doença inflamatória do intestino. a presente invenção também se refere a igfbp3 e usos dele para o diagnóstico, prognóstico ou uma doença intestinal, em particular, de enteropatia diabética ou doença inflamatória do intestino.
BR112017025995-8A 2015-06-04 2016-06-06 inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal BR112017025995A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15170679.3 2015-06-04
EP15170679 2015-06-04
PCT/EP2016/062790 WO2016193496A1 (en) 2015-06-04 2016-06-06 Igfbp3 and uses thereof

Publications (1)

Publication Number Publication Date
BR112017025995A2 true BR112017025995A2 (pt) 2018-08-14

Family

ID=53365866

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017025995-8A BR112017025995A2 (pt) 2015-06-04 2016-06-06 inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal

Country Status (17)

Country Link
US (2) US10682391B2 (pt)
EP (1) EP3302520B1 (pt)
JP (1) JP6937745B2 (pt)
KR (1) KR102141446B1 (pt)
CN (1) CN107921094B (pt)
AU (1) AU2016272044B2 (pt)
BR (1) BR112017025995A2 (pt)
CA (1) CA2986080C (pt)
EA (1) EA201792669A1 (pt)
ES (1) ES2834823T3 (pt)
HK (1) HK1249447A1 (pt)
IL (1) IL256020B (pt)
MX (1) MX2017015700A (pt)
NZ (1) NZ738100A (pt)
PL (1) PL3302520T3 (pt)
WO (1) WO2016193496A1 (pt)
ZA (1) ZA201708076B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016272045B2 (en) 2015-06-04 2018-04-19 Ospedale San Raffaele Srl Inhibitor of IGFBP3/TMEM219 axis and diabetes
KR102141446B1 (ko) 2015-06-04 2020-08-06 오스페달레 산 라파엘 에스.알.엘. Ｉｇｆｂｐ3 및 이의 용도
EP3534932A4 (en) 2016-11-01 2020-09-09 Virginia Commonwealth University TREATMENT OF DISEASES ASSOCIATED WITH IGFB3 AND ITS RECEPTOR
EP3632929A1 (en) 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antibodies and uses thereof
WO2021014351A1 (en) * 2019-07-23 2021-01-28 Novartis Ag Treatment comprising sglt inhibitors, e.g. sglt 1/2 inhibitors
JP2023501229A (ja) 2019-11-15 2023-01-18 エンテラ・エッセ・エッレ・エッレ Ｔｍｅｍ２１９抗体及びその治療的使用
WO2021099574A1 (en) 2019-11-21 2021-05-27 Enthera S.R.L. Igfbp3 antibodies and therapeutic uses thereof
CN117451995A (zh) * 2021-12-06 2024-01-26 上海市精神卫生中心（上海市心理咨询培训中心） 用于预测应激后精神心理症状发生的免疫检测试剂盒及应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
EP0854884A1 (en) 1996-04-17 1998-07-29 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6066464A (en) 1996-12-10 2000-05-23 Diagnostic Systems Laboratories, Inc. Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6448086B1 (en) 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
EP1290162A4 (en) 2000-05-17 2005-08-17 Univ Oregon Health Sciences INDUCTION OF APOPTOSIS AND INHIBITION OF CELL GROWTH BY PROTEIN 4.33 (P4.33)
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
AU2002232593A1 (en) 2000-10-27 2002-05-06 Oregon Health And Science University Novel mutant igbp-3 molecules that do not bind to igfs, but retain their ability to functionally bind igfbp-3 receptor
EP2341060B1 (en) 2000-12-12 2019-02-20 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
EA036531B1 (ru) 2003-11-05 2020-11-19 Роше Гликарт Аг Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение
EP1791565B1 (en) 2004-09-23 2016-04-20 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20090170133A1 (en) * 2005-04-19 2009-07-02 Irena Kirman Intact IGFBP-3 as a Colon Cancer Risk Factor in Patients With Inflammatory Bowel Disease
RU2515108C2 (ru) 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
WO2008153788A2 (en) 2007-05-30 2008-12-18 Albert Einstein College Of Medicine Of Yeshiva University Treatment of type 2 diabetes, metabolic syndrome, myocardial injury and neurodegeneration with humanin and analogs thereof
ES2617777T5 (es) 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
CA2825357C (en) 2011-02-24 2018-07-10 Inserm (Institut National De La Sante Et De La Recherche Medicale) Igfbp-3 derivatives and uses thereof
CA2858389A1 (en) * 2011-12-15 2013-06-20 The Royal Institution For The Advancement Of Learning/Mcgill University Soluble igf receptor fc fusion proteins and uses thereof
WO2013152989A2 (en) 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20160011207A1 (en) 2012-12-07 2016-01-14 Virginia Commonwealth University Diagnosis and therapy of chronic inflammation-induced disorders
KR102500071B1 (ko) 2014-10-23 2023-02-14 얀센 파마슈티카 엔.브이. Ｎｉｋ 억제제로서의 신규 화합물
AU2016272045B2 (en) 2015-06-04 2018-04-19 Ospedale San Raffaele Srl Inhibitor of IGFBP3/TMEM219 axis and diabetes
KR102141446B1 (ko) 2015-06-04 2020-08-06 오스페달레 산 라파엘 에스.알.엘. Ｉｇｆｂｐ3 및 이의 용도

Also Published As

Publication number Publication date
JP2018520212A (ja) 2018-07-26
US20200316168A1 (en) 2020-10-08
HK1249447A1 (zh) 2018-11-02
WO2016193496A9 (en) 2020-02-20
AU2016272044B2 (en) 2018-12-06
NZ738100A (en) 2019-09-27
EA201792669A1 (ru) 2018-06-29
IL256020A (en) 2018-01-31
JP6937745B2 (ja) 2021-09-22
ES2834823T3 (es) 2021-06-18
US20180172708A1 (en) 2018-06-21
EP3302520A1 (en) 2018-04-11
CN107921094B (zh) 2022-03-01
WO2016193496A1 (en) 2016-12-08
KR20180019152A (ko) 2018-02-23
MX2017015700A (es) 2018-11-09
CN107921094A (zh) 2018-04-17
CA2986080C (en) 2023-12-05
US10682391B2 (en) 2020-06-16
AU2016272044A1 (en) 2018-01-04
ZA201708076B (en) 2018-11-28
PL3302520T4 (pl) 2021-03-22
IL256020B (en) 2021-09-30
KR102141446B1 (ko) 2020-08-06
CA2986080A1 (en) 2016-12-08
EP3302520B1 (en) 2020-08-05
PL3302520T3 (pl) 2021-03-22

Similar Documents

Publication Publication Date Title
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
BR112018000691A2 (pt) inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
BR112015029318A2 (pt) marcadores específicos de caminhos para diagnóstico da síndrome do intestino irritável
BR112017008284A2 (pt) bifidobactérias ativadas e métodos para uso das mesmas
AR090339A1 (es) Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
BR112016029713A8 (pt) uso de uma carboximetilcelulose reticulada e uso de um agente gelificante
CR20120266A (es) Inmunoglobinas con dominio variable dual y usos de las mismas
CO6670524A2 (es) Proteínas de unión de dominio variable dual que se unen a ngf y al menos a un blanco adicional, y métodos para hacer y usar dichas proteínas de unión
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
BR112017002761A2 (pt) composições anti-metanogênicas e usos das mesmas
BR112016019592A8 (pt) Composto, uso de um composto, e, composição farmacêutica
BR112015028338A2 (pt) métodos de diagnóstico ou de auxílio no diagnóstico e de tratamento da doença inflamatória intestinal
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
BR112017004056A2 (pt) composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
NZ707035A (en) Gene signatures of inflammatory disorders that relate to the liver
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
BR112017025998A2 (pt) inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit
EP3285071A4 (en) Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
BR112018013272A2 (pt) composições e métodos para detectar e tratar câncer esofágico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2673 DE 29-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.